Advertisement
Advertisement
U.S. Markets open in 6 hrs 4 mins
Advertisement
Advertisement
Advertisement
Advertisement

Virios Therapeutics, Inc. (VIRI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
8.70+1.01 (+13.13%)
At close: 04:00PM EDT
8.70 0.00 (0.00%)
After hours: 06:44PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7.69
Open7.75
Bid0.00 x 1800
Ask0.00 x 2200
Day's Range7.51 - 8.86
52 Week Range3.30 - 8.86
Volume139,936
Avg. Volume20,758
Market Cap72.474M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.38
Earnings DateAug 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.00
  • Business Wire

    Virios Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update

    ATLANTA, August 11, 2022--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia, today announced financial results for the second quarter ended June 30, 2022.

  • Business Wire

    Virios Therapeutics, Inc. to Present at Investor Summit Group’s Q3 Virtual Conference

    ATLANTA, August 10, 2022--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, today announced that Greg Duncan, Chairman and CEO of Virios Therapeutics will be attending and presenting at the Q3 Virtual Investor Summit. During the presentation, the Company will provide an overview of its business and corporate strategy as well as upcoming key

  • Newsfile

    Virios Therapeutics: The 'Virus Hypothesis' That Stands to Change the Lives of 10M Americans

    Company's September Phase 2b trial results could be transformative for fibromyalgia patients New York, New York--(Newsfile Corp. - August 8, 2022) - PCG Digital -- Life may change for the better for the 10 million Americans suffering from fibromyalgia. The development-stage biotech Virios Therapeutics, Inc. (NASDAQ: VIRI) is anticipating the reporting of phase 2b treatment results for its lead fibromyalgia treatment candidate this September and continues to add value through its research and dev

Advertisement
Advertisement